News: vanderbilt

Next Page »

Photo: Lung Cancer Partnership

Friday, September 28th, 2012

Caroline Nebhan, right, a fourth-year student in the M.D./Ph.D. training program, explains a cancer research experiment to advocates from the National Lung Cancer Partnership who toured Vanderbilt-Ingram Cancer Center during their recent meeting in Nashville. Nebhan, who works in the research laboratory of William Pao, M.D., Ph.D., is studying the effects of a specific cancer […]

Target Acquired for Aggressive Tumor

Friday, September 28th, 2012

Angiosarcoma, a rare, aggressive tumor that arises from cells that line blood vessels, has a mortality rate of around 80 percent. Because of their constant contact with the blood stream, these tumors can spread quickly and freely throughout the body. The INK4a/ARF locus on chromosome 9 – a region that encodes tumor suppressor proteins – […]

LifeFlight goes pink for breast cancer awareness

Friday, September 28th, 2012

Nashville (Tenn.) – Vanderbilt LifeFlight is going pink during October to show its support for breast cancer awareness.LifeFlight medical crews will wear a special pink name badge on their flight suits and other staff will wear pink golf shirts. October is designated as National Breast Cancer Awareness Month, dedicated to raising awareness and educating individuals […]

Grant Renewal Boosts GI Cancer Research Program

Friday, September 21st, 2012

Vanderbilt-Ingram Cancer Center’s gastrointestinal Specialized Program of Research Excellence (SPORE) has been awarded its third round of funding by the National Cancer Institute (NCI). “We decided to roll the dice and propose high-risk, high-reward projects,” said Robert Coffey Jr., M.D., Ingram Professor of Cancer Research, professor of Medicine and Cell and Developmental Biology, and director […]

HER2 May Impact Lung Cancer Therapy

Friday, September 21st, 2012

Overcoming therapeutic resistance that inevitably develops is one of the major challenges in treating lung cancer. Non-small cell lung cancers that harbor mutations in the epidermal growth factor receptor (EGFR) are initially responsive to targeted therapies known as EGFR tyrosine kinase inhibitors (TKIs). However, most patients eventually develop resistance to these therapies. One such targeted […]

Cancer Wellness Program Launches ‘Thrivership’ Classes

Friday, September 21st, 2012

Adult cancer patients and survivors are invited to participate in Vanderbilt-Ingram Cancer Center’s new Thrivership Program, which is designed to restore wellness through physical activity, enhanced nutrition, body awareness and emotional well-being. During the six-week program, participants are invited to attend 90-minute classes which include guided exercise plus mindful movement along with interactive educational sessions […]

Stand Up to Cancer TV broadcast airs Sept. 7

Thursday, August 30th, 2012

Stand Up To Cancer (SU2C), the nonprofit organization that helps fund various Vanderbilt-Ingram Cancer Center (VICC) investigators, returns to prime time television for its third broadcast Friday, Sept. 7, at 7 p.m. The hourlong show featuring Hollywood celebrities, recording artists and sports figures will include special performances and a celebrity phone/multi-media bank that will allow […]

Gene Linked to Familial Prostate Cancer

Tuesday, August 28th, 2012

Family history is the best predictor of risk for prostate cancer, suggesting that the disease has a strong hereditary component. Recently, a heritable mutation in the HOXB13 gene was found to predispose men of European descent to prostate cancer. Jeffrey Smith, M.D., Ph.D., associate professor of Medicine and Cancer Biology, and colleagues initiated a study […]

Study Reveals Racial Disparities in Prostate Cancer Care

Thursday, August 23rd, 2012

A study led by investigators from Vanderbilt-Ingram Cancer Center (VICC), Nashville, Tenn., finds that black men with prostate cancer receive lower quality surgical care than white men. The racial differences persist even when controlling for factors such as the year of surgery, age, comorbidities and insurance status. Daniel Barocas, M.D., MPH, assistant professor of Urologic […]

New Method May Allow Personalized Clinical Trial for Cancer Therapies

Tuesday, August 14th, 2012

A new tool to observe cell behavior has revealed surprising clues about how cancer cells respond to therapy – and may offer a way to further refine personalized cancer treatments. The approach, developed by investigators at Vanderbilt-Ingram Cancer Center, shows that erlotinib – a targeted therapy that acts on a growth factor receptor mutated in […]